Effect of beta₂-adrenergic agonist and resistance training on maximal oxygen uptake and muscle oxidative enzymes in men

TY - JOUR

T1 - Effect of beta2-adrenergic agonist and resistance training on maximal oxygen uptake and muscle oxidative enzymes in men

AU - Lemminger, Anders Krogh

AU - Jessen, Søren

AU - Habib, Sajad

AU - Onslev, Johan Dejgaard

AU - Xu, Stella Feng Sheng

AU - Backer, Vibeke

AU - Bangsbo, Jens

AU - Hostrup, Morten

N1 - This article is protected by copyright. All rights reserved.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - While beta2-adrenoceptor stimulation has been shown to increase lean mass and to alter metabolic properties of skeletal muscle, adaptations in muscle oxidative enzymes and maximal oxygen uptake ((Formula presented.) O2max) in response to beta2-adrenergic agonist treatment are inadequately explored in humans, particularly in association with resistance training. Herein, we investigated beta2-adrenergic-induced changes in (Formula presented.) O2max, leg and arm composition, and muscle content of oxidative enzymes in response to treatment with the selective beta2-adrenergic agonist terbutaline with and without concurrent resistance training in young men. Forty-six subjects were randomized to 4 weeks of lifestyle maintenance (n = 23) or resistance training (n = 23). Within the lifestyle maintenance and resistance training group, subjects received daily terbutaline (8 × 0.5 mg) (n = 13) or placebo (n = 10) treatment. No apparent treatment by training interactions was observed during the study period. Terbutaline increased leg and arm lean mass with the intervention, whereas no treatment differences were observed in absolute (Formula presented.) O2max and incremental peak power output (iPPO). Treatment main effects were observed for (Formula presented.) O2-reserve (P <.05), (Formula presented.) O2max relative to body mass (P <.05), (Formula presented.) O2max relative to leg lean mass (P <.01), and iPPO relative to leg lean mass, in which terbutaline had a negative effect compared with placebo. Furthermore, content of electron transport chain complex I-V decreased by 11% (P <.05) for terbutaline compared with placebo. Accordingly, chronic treatment with the selective beta2-adrenergic agonist terbutaline may negatively affect (Formula presented.) O2max and iPPO in relative terms, but not in absolute.

AB - While beta2-adrenoceptor stimulation has been shown to increase lean mass and to alter metabolic properties of skeletal muscle, adaptations in muscle oxidative enzymes and maximal oxygen uptake ((Formula presented.) O2max) in response to beta2-adrenergic agonist treatment are inadequately explored in humans, particularly in association with resistance training. Herein, we investigated beta2-adrenergic-induced changes in (Formula presented.) O2max, leg and arm composition, and muscle content of oxidative enzymes in response to treatment with the selective beta2-adrenergic agonist terbutaline with and without concurrent resistance training in young men. Forty-six subjects were randomized to 4 weeks of lifestyle maintenance (n = 23) or resistance training (n = 23). Within the lifestyle maintenance and resistance training group, subjects received daily terbutaline (8 × 0.5 mg) (n = 13) or placebo (n = 10) treatment. No apparent treatment by training interactions was observed during the study period. Terbutaline increased leg and arm lean mass with the intervention, whereas no treatment differences were observed in absolute (Formula presented.) O2max and incremental peak power output (iPPO). Treatment main effects were observed for (Formula presented.) O2-reserve (P <.05), (Formula presented.) O2max relative to body mass (P <.05), (Formula presented.) O2max relative to leg lean mass (P <.01), and iPPO relative to leg lean mass, in which terbutaline had a negative effect compared with placebo. Furthermore, content of electron transport chain complex I-V decreased by 11% (P <.05) for terbutaline compared with placebo. Accordingly, chronic treatment with the selective beta2-adrenergic agonist terbutaline may negatively affect (Formula presented.) O2max and iPPO in relative terms, but not in absolute.

KW - Faculty of Science

KW - Salbutamol

KW - Beta2-agonist

KW - Strength training

KW - Endurance

KW - Doping

KW - Performance

KW - Exercise

U2 - 10.1111/sms.13544

DO - 10.1111/sms.13544

M3 - Journal article

C2 - 31442335

SN - 0905-7188

VL - 29

SP - 1881

EP - 1891

JO - Scandinavian Journal of Medicine & Science in Sports

JF - Scandinavian Journal of Medicine & Science in Sports

IS - 12

ER -